Related Experiment Videos
Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy
Gerd Schmitz1, Wolfgang Drobnik
1Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany. gerd.schmitz@klinik.uni-regensburg.de
Insights
Statins effectively lower cholesterol and prevent cardiovascular disease but can cause severe side effects. Pharmacogenomics can identify patients at risk for adverse reactions or non-response to statin therapy.
Area of Science:
- Pharmacology
- Pharmacogenomics
- Cardiovascular Disease Prevention
Background:
- Cholesterol-lowering therapy, primarily using statins (HMG-CoA reductase inhibitors), is crucial for preventing cardiovascular disease.
- Statins are effective but can cause severe adverse effects like myopathy, especially with drug interactions or high doses.
- Individual responses to statins vary, necessitating methods to predict adverse reactions or treatment efficacy.
Purpose of the Study:
- To review the current understanding of statin pharmacology.
- To explore the role of pharmacogenomics in predicting statin response and adverse effects.
- To highlight the need for personalized approaches in statin therapy.
Main Methods:
- Literature review of clinical trials and pharmacogenomic studies on statin therapy.
- Analysis of pharmacokinetic and pharmacodynamic factors influencing statin efficacy and toxicity.
- Synthesis of current knowledge on genetic variability and drug response.
Main Results:
- Statins significantly reduce cardiovascular event risk.
- Adverse effects like myopathy are linked to drug interactions and high-dose therapy.
- Genetic factors play a role in individual responses to statins, impacting both efficacy and safety.
Conclusions:
- Personalized statin therapy, guided by pharmacogenomics, is essential for optimizing cardiovascular disease prevention.
- Identifying patients at risk for adverse drug reactions or non-response can improve treatment outcomes.
- Further research into pharmacogenomic markers will enhance the safe and effective use of statins.
Abstract:
Cholesterol-lowering therapy is the central approach in the primary and secondary prevention of cardiovascular disease, the leading cause of death in industrialized countries. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are currently the most potent and widely used cholesterol-lowering drugs. Large-scale clinical trials unequivocally demonstrated the efficacy of statin treatment in reducing the risk of cardiovascular events. In general, HMG-CoA reductase inhibitors are well tolerated, although in a minority of patients severe adverse effects like myopathy or rhabdomyolysis may develop. The incidence of this potentially life-threatening side effects increases with co-adminstration of drugs that are metabolized via the same pharmacokinetic pathways or at high-dose statin therapy. The recent focus on the pleiotropic effects of statins that are more frequently observed at higher doses and the conclusion drawn from the large statin trials that low-density lipoprotein (LDL)-cholesterol is "the lower the better", may need careful consideration in individuals at risk of adverse drug reactions. On the other hand, not all patients respond to statin therapy with a reduction in coronary heart disease (CHD) risk. It is therefore of interest to develop diagnostic test systems, which would allow to identify patients at increased risk of adverse drug reactions or patients with a lack of therapeutic effect. Beside exogenous factors, genetic variability determines the response of an individual to drug therapy and the analysis of genetic variants affecting pharmacokinetic or pharmacodynamic aspects of drug therapy is the subject of pharmacogenomics. This review summarizes current knowledge of the pharmacology and the pharmacogenomics of statin therapy.